Norges Bank Global Blood Therapeutics, Inc. Transaction History

Norges Bank

  • $716 Trillion
  • Q3 2024

Shares

36 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 13, 2023
SELL
N/A
-960,504 Closed
0 $0
Q2 2023

Aug 14, 2023
SELL
N/A
-572,795 Closed
0 $0
Q3 2022

Nov 13, 2023
BUY
$32.4 - $68.18 $31.1 Million - $65.5 Million
960,504 New
960,504 $65.4 Million
Q2 2022

Aug 14, 2023
BUY
$22.3 - $37.39 $12.8 Million - $21.4 Million
572,795 New
572,795 $18.3 Million
Q1 2022

May 12, 2023
BUY
$25.68 - $35.59 $13.6 Million - $18.8 Million
529,590 New
529,590 $18.3 Million
Q1 2022

May 09, 2022
SELL
$25.68 - $35.59 $5.19 Million - $7.19 Million
-202,121 Closed
0 $0
Q4 2021

Mar 09, 2022
BUY
$24.9 - $40.26 $5.03 Million - $8.14 Million
202,121 New
202,121 $5.92 Million
Q3 2021

Nov 14, 2022
BUY
$25.48 - $37.34 $9.37 Million - $13.7 Million
367,778 New
367,778 $9.37 Million
Q3 2021

Nov 05, 2021
SELL
$25.48 - $37.34 $9.37 Million - $13.7 Million
-367,778 Closed
0 $0
Q2 2021

Aug 15, 2022
BUY
$32.46 - $43.42 $11.9 Million - $16 Million
367,778 New
367,778 $12.9 Million
Q2 2021

Aug 10, 2021
SELL
$32.46 - $43.42 $14.5 Million - $19.4 Million
-447,726 Closed
0 $0
Q1 2021

May 09, 2022
BUY
$38.94 - $50.85 $17.4 Million - $22.8 Million
447,726 New
447,726 $18.2 Million
Q1 2021

May 07, 2021
SELL
$38.94 - $50.85 $21.6 Million - $28.2 Million
-554,284 Closed
0 $0
Q4 2020

Mar 02, 2021
BUY
$37.65 - $63.77 $20.9 Million - $35.3 Million
554,284 New
554,284 $24 Million
Q4 2020

Feb 10, 2021
SELL
$37.65 - $63.77 $20.7 Million - $35.1 Million
-550,540 Closed
0 $0
Q3 2020

Nov 12, 2021
BUY
$52.76 - $74.49 $29 Million - $41 Million
550,540 New
550,540 $30.4 Million
Q3 2020

Nov 10, 2020
SELL
$52.76 - $74.49 $28.6 Million - $40.4 Million
-543,023 Closed
0 $0
Q2 2020

Aug 13, 2021
BUY
$48.73 - $81.82 $26.5 Million - $44.4 Million
543,023 New
543,023 $34.3 Million
Q2 2020

Aug 07, 2020
SELL
$48.73 - $81.82 $31.1 Million - $52.3 Million
-639,082 Closed
0 $0
Q1 2020

May 07, 2021
BUY
$41.72 - $87.2 $26.7 Million - $55.7 Million
639,082 New
639,082 $32.7 Million
Q1 2020

May 08, 2020
SELL
$41.72 - $87.2 $26.7 Million - $55.7 Million
-639,082 Closed
0 $0
Q4 2019

Mar 03, 2020
BUY
$45.7 - $81.86 $29.2 Million - $52.3 Million
639,082 New
639,082 $50.8 Million
Q4 2019

Feb 12, 2020
SELL
$45.7 - $81.86 $28.6 Million - $51.2 Million
-625,892 Closed
0 $0
Q3 2019

Nov 13, 2020
BUY
$45.35 - $57.91 $28.4 Million - $36.2 Million
625,892 New
625,892 $30.4 Million
Q3 2019

Nov 08, 2019
SELL
$45.35 - $57.91 $28.4 Million - $36.2 Million
-625,892 Closed
0 $0
Q2 2019

Aug 13, 2020
BUY
$52.6 - $63.29 $32.9 Million - $39.6 Million
625,892 New
625,892 $32.9 Million
Q2 2019

Aug 09, 2019
SELL
$52.6 - $63.29 $28.9 Million - $34.7 Million
-548,949 Closed
0 $0
Q1 2019

May 11, 2020
BUY
$39.99 - $53.48 $4.59 Million - $6.13 Million
114,690 Added 26.41%
548,949 $29.1 Million
Q4 2018

Mar 04, 2019
BUY
$31.54 - $46.67 $13.7 Million - $20.3 Million
434,259 New
434,259 $17.8 Million
Q4 2018

Feb 08, 2019
SELL
$31.54 - $46.67 $8.25 Million - $12.2 Million
-261,695 Closed
0 $0
Q3 2018

Nov 12, 2019
BUY
$38.0 - $51.1 $9.94 Million - $13.4 Million
261,695 New
261,695 $9.95 Million
Q3 2018

Nov 09, 2018
SELL
$38.0 - $51.1 $9.94 Million - $13.4 Million
-261,695 Closed
0 $0
Q2 2018

Aug 12, 2019
BUY
$38.7 - $50.15 $10.1 Million - $13.1 Million
261,695 New
261,695 $11.8 Million
Q2 2018

Jul 23, 2018
SELL
$38.7 - $50.15 $9.7 Million - $12.6 Million
-250,608 Closed
0 $0
Q1 2018

May 15, 2019
BUY
$39.6 - $65.9 $8 Million - $13.3 Million
202,008 Added 415.65%
250,608 $12.1 Million
Q3 2016

Nov 13, 2017
BUY
N/A
48,600
48,600 $0

Others Institutions Holding GBT

# of Institutions
8
Shares Held
288K
Call Options Held
0
Put Options Held
0
View Full List

About Global Blood Therapeutics, Inc.

GBT Quotes by TradingView
  • Ticker GBT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,476,200
  • Market Cap $4.62B
  • Description
  • Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...
More about GBT
Track This Portfolio

Track Norges Bank Portfolio

Follow Norges Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

News

Stay updated on Norges Bank with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email